Related Experiment Videos
Wegener's granulomatosis in the elderly
Arthritis and Rheumatism
|September 1, 1986
Summary
Wegener's granulomatosis (WG) diagnosis and treatment in elderly patients may be delayed, leading to worse outcomes. Aggressive therapy, like cyclophosphamide, is effective but often avoided in older adults.
Area of Science:
- Rheumatology
- Internal Medicine
- Pathology
Background:
- Wegener's granulomatosis is a systemic necrotizing granulomatous vasculitis.
- The disease typically affects individuals in their forties.
- Cyclophosphamide is an effective treatment for Wegener's granulomatosis.
Purpose of the Study:
- To investigate the diagnosis and treatment of Wegener's granulomatosis in elderly patients (≥60 years).
- To determine if a reluctance to use aggressive therapy in the elderly impacts diagnosis and treatment.
- To assess if delayed diagnosis and treatment in the elderly lead to increased morbidity and mortality.
Main Methods:
- Retrospective chart review.
- Analysis of patient demographics, diagnostic delays, treatment regimens, and outcomes.
- Comparison of elderly patients with younger patients.
Main Results:
- Elderly patients may experience delays in diagnosis and treatment initiation.
- Aggressive therapies like cyclophosphamide might be underutilized in the elderly population.
- Delayed treatment in the elderly is associated with higher rates of morbidity and mortality.
Conclusions:
- A tendency to avoid aggressive therapy in elderly patients with Wegener's granulomatosis may contribute to diagnostic delays.
- These delays can result in worse health outcomes for elderly patients.
- Further research is needed to optimize treatment strategies for Wegener's granulomatosis in older adults.